Zobrazeno 1 - 10
of 144
pro vyhledávání: '"M., Pellicelli"'
Autor:
Rodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, Luigi Elio Adinolfi, Antonio Ascione, Giorgio Barbarini, Angelo Barlattani, Giuseppe Cariti, Raffaele Cozzolongo, Basilio Fimiani, Ruggiero Francavilla, Caterina Furlan, Giovanni Garrucciu, Vincenzo Iovinella, Luca Rinaldi, Massimo Marignani, Paola Begini, Valeria Pace Palitti, Adriano M Pellicelli, Gaetano Scifo, Antonio Facciorusso, Luca Giacomelli, Aashni Shah, Gaetano Bertino, Serena Perazzo, Giampaolo Bresci, Antonio Izzi
Publikováno v:
Drugs in Context, Vol 9, Pp 1-6 (2020)
Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to
Externí odkaz:
https://doaj.org/article/bc98ae33658645cdb80df67be1e48624
Autor:
M., Pellicelli1 michela.pellicelli@unipv.it, E., Cerruti elisacerruti@gmail.it, C., Casalegno2 cecilia.casalegno@unito.it, G., Bagnato3 giovanna.bagnato@unito.it
Publikováno v:
Economia Aziendale Online. 2023, Vol. 14 Issue 3, p1-3. 3p.
Autor:
Adriano M. Pellicelli, Cecilia D’Ambrosio, Maria L. Dessanti, Roberto Villani, Lucia Fondacaro, Lucia Miglioresi, Lucia R. Grillo, Arnaldo Andreoli
Publikováno v:
Annals of Hepatology, Vol 14, Iss 5, Pp 756-761 (2015)
Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associate
Externí odkaz:
https://doaj.org/article/dc93dcb9a67c4fb7b62aede6d14206ec
Autor:
Adriano M. Pellicelli, M.D., Pascal Vignally, Vincenzo Messina, Antonio Izzi, Ettore Mazzoni, Angelo Barlattani, Donato Bacca, Mario Romano, Fabrizio Mecenate, Tommaso Stroffolini, Caterina Furlan, Antonio Picardi, Umberto V. Gentilucci, Roberto Gulminetti, Maria E. Bonaventura, Roberto Villani, Cecilia D’Ambrosio, Amerigo Paffetti, Cristina Mastropietro, Massimo Marignani, Lucia Fondacaro, Giuseppe Cerasari, Arnaldo Andreoli, Giorgio Barbarini
Publikováno v:
Annals of Hepatology, Vol 13, Iss 4, Pp 376-385 (2014)
Background and rationale of the study. Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was
Externí odkaz:
https://doaj.org/article/6e4b7edbe30049869b71d67761191c31
Autor:
Giampaolo Bresci, Adriano M. Pellicelli, Luigi Elio Adinolfi, Luca Rinaldi, Giovanni Garrucciu, Aashni Shah, Umberto Vespasiani Gentilucci, G. Scifo, Paola Begini, Antonio Facciorusso, Serena Perazzo, A. Barlattani, Giorgio Barbarini, Caterina Furlan, Rodolfo Sacco, Antonio Ascione, Raffaele Cozzolongo, Massimo Marignani, Vincenzo Messina, Giuseppe Cariti, Gaetano Bertino, Basilio Fimiani, Ruggiero Francavilla, Vincenzo Iovinella, Luca Giacomelli, Valeria Pace Palitti, Antonio Izzi
Publikováno v:
Drugs in Context, Vol 9, Pp 1-6 (2020)
Drugs in Context
Drugs in Context
Background The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2261ad1095f36a35659963fda02ddb
https://www.drugsincontext.com/sustained-virological-response-in-patients-with-hcv-treated-with-daclatasvir-sofosbuvir-with-or-without-ribavirin-a-large-field-practice-study
https://www.drugsincontext.com/sustained-virological-response-in-patients-with-hcv-treated-with-daclatasvir-sofosbuvir-with-or-without-ribavirin-a-large-field-practice-study
Publikováno v:
Annals of Hepatology, Vol 11, Iss 6, Pp 951-954 (2012)
Introduction. Porphyria cutanea tarda (PCT) is the most common type of porphyria. The strong association between PCT and hepatitis C virus (HCV) infection is well established. Although antiviral treatment of chronic hepatitis C may improve PCT in som
Externí odkaz:
https://doaj.org/article/c88406d8cfc149589465399bd7d0aea6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Giovanni Regine, Luigi Rigacci, Valerio Zoli, Valerio Giannelli, Valeria Pellicelli, Adriano M. Pellicelli, Giuseppe Maria Ettorre, Enrico Carmenini, Andrea Cortese
Publikováno v:
Oxford Medical Case Reports
The favorable impact of antiviral therapy on low-grade hepatitis C virus (HCV)-related non-Hodgkin lymphoma manifesting as marginal zone lymphoma (MZL) has been reported in some clinical studies. However, primary HCV-related marginal zone lymphomas (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7048d8c98c5c29981883910f05976295
https://doi.org/10.1093/omcr/omab022
https://doi.org/10.1093/omcr/omab022
Autor:
Michele Diana, Valerio Giannelli, Emanuele Felli, Marco Colasanti, Adriano M. Pellicelli, Giuseppe Maria Ettorre, Edoardo Maria Muttillo, Eric Felli, Riccardo Memeo
Publikováno v:
HPB : the official journal of the International Hepato Pancreato Biliary Association. 23(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c6d189b635d594daf1d06e08ece4e2
https://pubmed.ncbi.nlm.nih.gov/33836978
https://pubmed.ncbi.nlm.nih.gov/33836978
Autor:
Anna Morgando, Mauro Viganò, Ana Lleo, Maurizio Pompili, Elisabetta De Gasperi, Daphne D’Amato, Alessandro Mussetto, Nora Cazzagon, Pietro Invernizzi, Francesca Colapietro, Vincenzo Ronca, Sara Labanca, Ester Vanni, M.R. Cannavò, Francesco Losito, Ernesto Claar, G. Scifo, Giovanni Galati, Umberto Vespasiani-Gentilucci, Silvia Storato, Alessio Gerussi, Grazia Anna Niro, Antonio Izzi, Barbara Omazzi, Antonio De Vincentis, Valentina Feletti, Giuseppe Grassi, Valeria Pace Palitti, Clara Mancuso, Vincenza Calvaruso, Evelise Frazzetto, Roberto Boldizzoni, Marco Marzioni, Floriano Rosina, Andrea Palermo, Antonino Picciotto, Valentina Bellia, Gaetano Bertino, Italian Pbc Registry, Guido Poggi, Rodolfo Sacco, Domenico Alvaro, Luigi Muratori, Maria Vinci, Marie Graciella Pigozzi, Raffaele Cozzolongo, Natalia Terreni, Annarosa Floreani, Maurizio Russello, Marco Distefano, Rinaldo Pellicano, Maria D'Antò, Marco Carbone, Rosanna Venere, R. Fontana, Antonio Picardi, Silvia Casella, S. E. O'Donnell, Federica Malinverno, Stefano Fagiuoli, Laura Cristoferi, Luchino Chessa, Giacomo Mulinacci, Pietro Pozzoni, Antonino Castellaneta, Giulia Marconi, Adriano M. Pellicelli, Francesca Romana Ponziani, Leonardo Baiocchi
Publikováno v:
JHEP Reports, Vol 3, Iss 2, Pp 100248-(2021)
JHEP Reports
JHEP Reports
Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61fe7d019f05517ffe25526686712b24
http://hdl.handle.net/20.500.11769/503362
http://hdl.handle.net/20.500.11769/503362
